Soleno Therapeutics tumbles despite Q3 earnings, revenue beat
Reprogrammed Interchange LLC, a ten percent owner of Vor Biopharma Inc. (NASDAQ:VOR), reported selling 73,676 shares of common stock on October 15 and 16, 2025, for a total value of $2.35 million. The sales prices ranged from $30.4548 to $32.7733. The transactions come as VOR’s stock has shown remarkable momentum, with InvestingPro data showing a 123% surge over the past six months, despite the company’s current market capitalization of approximately $200 million.
The transactions, which were detailed in a Form 4 filing with the Securities and Exchange Commission, show that on October 15, Reprogrammed Interchange sold 14,851 shares at a weighted average price of $31.0496, with individual prices ranging from $30.505 to $31.50, for approximately $461,147. The same day, an additional 48,910 shares were sold at an average price of $32.0459, in a range of $31.51 to $32.505, totaling $1,567,243. Also on October 15, 7,894 shares were sold at an average price of $32.7733, with prices ranging from $32.51 to $33.01, for a total of $258,724. On October 16, the entity sold 2,021 shares at a weighted average price of $30.4548, in a price range of $30.05 to $30.50, for $61,540. InvestingPro data indicates the stock’s high volatility, with a beta of 2.08 and analyst price targets ranging widely from $8 to $64.
Following these transactions, Reprogrammed Interchange LLC directly holds 1,204,442 shares of Vor Biopharma.
The filing was jointly signed by Reid Hoffman, who may be deemed a beneficial owner of the securities held by Reprogrammed Interchange LLC, and Frank Huang, Manager of Reprogrammed Interchange LLC.
In other recent news, Vor Biopharma announced that its collaborator RemeGen’s Phase 3 study of telitacicept in primary Sjögren’s disease met both its primary and secondary endpoints. The trial, conducted in China, demonstrated significant improvements, with 71.8% of patients receiving the 160mg dose achieving a clinically meaningful reduction in disease activity at 24 weeks. These results have prompted Vor Biopharma to plan a presentation of the clinical data at the upcoming ACR Convergence 2025 conference in Chicago. Additionally, Baird upgraded Vor Biopharma’s stock rating from Neutral to Outperform, citing the potential of telitacicept and raising the price target from $20.00 to $64.00. The upgrade reflects Baird’s positive assessment of the therapy’s promising results in clinical trials. Furthermore, Vor Biopharma filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock. These shares would be issued upon the exercise of outstanding warrants, including those issuable to a subsidiary of RemeGen and private placement investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.